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BRCA1 and BRCA2 Testing: Weighing the Demand against the Benefits
P. Devilee
Departments of Human Genetics and Pathology, Leiden University Medical Center, Leiden, The Netherlands
Mutations in the BRCA1 and BRCA2 genes in females
confer strongly elevated risks of developing cancers of
the breast and ovary. Ever since BRCA1 and BRCA2
were identified in 1994 and 1995, respectively, there has
been a continuous debate as to whether (presympto-
matic) testing for these mutations is beneficial, in clinical
terms, and, if so, who should be eligible for testing (Col-
lins 1996). Initial estimates of the gene frequency of
BRCA1 in the general population suggested that disease-
causing mutations would be present in 1 in every 833
women (Ford et al. 1995). This prevalence represents
the total mutational load in BRCA1, which we now
know to consist of several hundred different DNA
changes (Breast Cancer Information Core website). To-
gether with the absence of an undisputed cancer pre-
vention option for mutation carriers, such prevalence
makes widespread population screening for these mu-
tations not only unfeasible, but also undesirable. Ac-
cordingly, many advisory bodies, including the one un-
der the auspices of the American Society for Clinical
Oncology (ASCO Public Issues Committee 1996), have
recommended that testing be restricted to women at high
risk of developing breast or ovarian cancer. In general,
such risk is indicated by a strong positive family history
of one or both of these diseases.
However, with the discovery that several founder mu-
tations in BRCA1 and BRCA2 occur at high frequencies
in certain ethnic populations, the technical and financial
limitations on such testing become less inhibitory. This
is the case for the BRCA1 mutations 185delAG and
5382insC, the BRCA2 mutation 6174delT in the Ash-
kenazi Jewish population, and the BRCA2 mutation
999del5 in the Icelandic population. Several anonymous
surveys have indicated that slightly more than 2% of
the Ashkenazim carry one of the three foundermutations
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(Struewing et al. 1995, 1997; Oddoux et al. 1996; Roa
et al. 1996; Fodor et al. 1998). A rapid and sensitive
assay for these mutations is already commercially avail-
able or easily designed at fairly low laboratory costs.
Does this pave the way toward broad community-based
screening among the Ashkenazi Jews for these muta-
tions, not just among those clearly at greater risk as
indicated by their family histories? The data presented
by Hartge and coworkers (1999 [in this issue]) indicate
that this is not so straightforward. These authors com-
pared the results of anonymous genetic testing of the
three BRCA1/BRCA2 founder mutations in 5,318 Jew-
ish men and women from the Washington, DC, area to
personal and family histories of cancer as obtained from
questionnaires completed by the participants. In all sub-
groups defined by age and cancer history, fewer muta-
tions were found in this community sample than in clin-
ical series studied to date.
If anywhere, the demand for testing is expected to be
highest among individuals with a personal or family his-
tory of breast or ovarian cancer. What proportion of
these individuals can be expected to carry a deleterious
mutation in BRCA1 or BRCA2? The Breast Cancer
Linkage Consortium (BCLC) has estimated the risks of
breast cancer conferred by BRCA1 mutations to be
∼50% by age 50 years and ∼85% by age 70 years (Ford
et al. 1994) (fig. 1). Combining this penetrance with the
prevalence of the 185delAG mutation in BRCA1 among
Ashkenazi Jews, one can predict that ∼19% of all in-
dividuals diagnosed with breast cancer by age 50 years,
and ∼9% of individuals diagnosed by age 70 years, are
carriers of this mutation. Similar proportions are ex-
pected to carry the 6174delT in BRCA2, given its age-
dependent penetrance (Ford et al. 1998) and prevalence
rate (Oddoux et al. 1996; Roa et al. 1996). Up to 40%
of all of Ashkenazi Jewish breast cancer patients aged
!50 years could thus be carriers of either of the known
founder mutations in BRCA1 and BRCA2, providing a
good rationale for broad testing. Yet Hartge et al. (1999)
find only 9% of all patients with breast cancer (and 14%
of patients aged !50 years) to carry the 185delAG,
5382insC, or 6174delT mutation—less than half the
proportion predicted by the BCLC estimates. Nonethe-
less, their findings are supported by two earlier studies
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Figure 1 Comparison of cumulative breast cancer risk estimates conferred by BRCA1 and BRCA2. The estimates of the Breast Cancer
Linkage Consortium are taken from Ford et al. (1995; 1998), whereas those for the 185delAG mutation in BRCA1 and the 999del5 mutation
in BRCA2 were taken from Struewing et al. (1997) and Thorlacius et al. (1998), respectively.
(Abeliovich et al. 1997; Fodor et al. 1998), that detected
totals of 6.7% and 13.4%, respectively, among unse-
lected patients with breast cancer (tables 1 and 2). Even
studies selecting early-onset cases find fewer carriers than
expected on this basis. How can this difference be ex-
plained? Hartge et al. (1999) were able to exclude lower
overall prevalence rates for the three mutations in their
particular study population, since the observed 2% ac-
cords very well with other studies of other Ashkenazi
Jewish populations. More likely, the risk estimates de-
rived by the BCLC are not applicable to the population
studied by Hartge et al. (1999). Indeed, previous analysis
of the same population survey estimated the cumulative
breast cancer risk among the Washington, DC, Ashke-
nazi Jewish carriers at 33% by age 50 years and 56%
by age 70 years (Struewing et al. 1997) (fig. 1). There
were no significant differences between the estimates for
the 185delAG, 5382insC, and 6174delT mutations. Al-
though these estimates would already imply lower at-
tributable risks associated with BRCA1 and BRCA2, the
observed breast cancer risk in noncarriers (13% by age
70) was also slightly higher than expected. Hence the
“genetic burden” caused by BRCA1/BRCA2 among pa-
tients with breast cancer diagnosed before age 70 years
(i.e., the difference between genetic and nongenetic
breast cancer) is in fact only 6% in this population.
A similar discrepancy between risk estimates of the
BCLC and those derived from population studies was
also seen for the BRCA2 999del5 mutation in the Ice-
landic population (Thorlacius et al. 1998). This muta-
tion was found to confer a cumulative breast cancer risk
of 37% by age 70 years, less than half of what was
calculated by the BCLC (fig. 1). This highlights an im-
portant issue currently attracting much attention within
the breast cancer genetics research community. The
BCLC estimates derive from 237 families selected for
having at least four cases of breast cancer and any num-
ber of ovarian cancer (Ford et al. 1998). It has been
argued that this has caused a strong bias toward higher
cumulative risk estimates. However, we should be cau-
tious about dismissing the BCLC risk estimates on these
grounds, for several reasons.
First, there are important methodological differences
in the statistical analyses between the BCLC studies and
the currently available population studies. The BCLC
studies have used a LOD score method that maximizes
the LOD score over a range of penetrances (Ford et al.
1994, 1998; Easton et al. 1995). This is independent of
the type of mutation in the disease locus, since it requires
linkage data for flanking markers (hence the selection
of larger families, for the analysis to be informative).
The genetic status of individual members of the families
(affecteds and nonaffecteds alike) can be determined
with great certainty. This is subsequently matched with
clinical status, which, in most of the families under anal-
ysis, was often confirmed by histology or medical charts.
Struewing et al. (1997) derive cancer risks by comparing
the history of cancer among the first-degree relatives of
carriers with that among the first-degree relatives of non-
carriers. Cancer ascertainment in first-degree relatives
relies almost entirely on interview of the index patient.
Carrier status is determined only in screened individuals,
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Table 1
Prevalence of BRCA1 among Ashkenazi Jewish Breast Cancer Patients
Geographic Origin Selection Criteria
Number
Tested
Number Positive
(%) Reference
New York (Memorial Sloan-Kettering) Age !42 years 80 16 (20)a Offit et al. (1996)
Boston metropolitan area Age 30–40 years 35 6 (17)a FitzGerald et al. (1996)
New York metropolitan area None 268 10 (3.7)b Fodor et al. (1998)
Israel (Jerusalem) None 178 16 (8.9)b Abeliovich et al. (1997)
Washington, DC, area None 288 15 (5.2)b Hartge et al. (1999)
a 185delAG only.
b 185delAG and 5382insC combined.
on which basis one can estimate probabilities of disease
among first-degree relatives. Hence, the relationship be-
tween disease and carrier status in first-degree relatives
is less certain than in the linkage studies. (In the Icelandic
study, data on cancer in first-degree relatives were avail-
able from the cancer registry, alleviating the cancer-as-
certainment problem.) Furthermore, the outcome of this
analysis in terms of BRCA1/BRCA2-conferred cancer
risks is also inherently dependent on the overall cancer
incidence in the control (noncarrier) population. As
noted, the breast cancer risk in the community sample
studied by Struewing et al. (1997) was already slightly
higher than expected. Whether these methodological dif-
ferences explain the differences in penetrance estimates
is not clear at present, but it would be interesting to
apply the LOD score method to a set of high-risk Ash-
kenazi Jewish families selected from the Washington,
DC, area, for which all breast cancers are ascertained
by chart analysis.
Second, besides the selection of “high-risk” families
by the BCLC, additional fundamental differences with
a community-based sample exist, which could influence
the outcome of risk estimates. The BCLC studies have
included families with a variety of different ethnic back-
grounds—European, Icelandic, and North American.
We can expect the mutational spectra of BRCA1 and
BRCA2, as well as the influence of environmental and
genetic modifiers, to be more diverse among the families
studied by the BCLC, compared with a single ethnic
subgroup. Mutation-specific breast cancer risks like
those reported for ovarian cancer (Gayther et al. 1995,
1997) could exist for BRCA1 and BRCA2. The differ-
ence in overall breast cancer incidence between different
populations is generally ascribed to differences in life-
style or other environmental impact (Willett 1989), and
studies analyzing the effect of such factors on BRCA1/
BRCA2-conferred cancer risks are currently under way
(Narod et al. 1995; Ursin et al. 1997; Brunet et al. 1998).
Whether or not genetic modifiers of these risks actually
exist is uncertain. This would require formal statistical
analysis of BRCA1- or BRCA2-linked families for the
presence of risk heterogeneity between families; such
analyses have not yet been done for breast cancer. Yet
some evidence has been obtained for a genetic modifier
of the ovarian cancer risk caused by BRCA1 (Phelan et
al. 1996). It is conceivable that differences in allele fre-
quencies at such loci exist between populations. Focus-
ing on a population with a particular ethnic background
could then draw out the effect of a specific interaction
between a particular mutation and any of these modi-
fying components. Clearly, the risks derived from pop-
ulation studies thus far concern specific BRCA1 and
BRCA2mutations andmay not apply to carriers of other
mutations. This underscores the importance of carrying
out surveys in other populations, even though this in-
volves a daunting amount of work relative to surveys in
founder populations, because of the lower overall
BRCA1 and BRCA2 prevalence.
Third, we should be aware that the same mutation
could cause different cancer risks in different families,
through modifying effects such as outlined above. If this
is the case, population-based estimates might represent
the average of considerable risk heterogeneity. Hartge et
al. (1999) found 1.2% of all investigated subjects with-
out a personal or family history of breast or ovarian
cancer (∼45 individuals) to be carriers of a BRCA1 or
BRCA2 mutation. Of course, there may be errors in the
reporting of cancers in relatives, and in some families,
particularly smaller ones, there may be a deficit of po-
tential female carriers. But this observation has been
made by others as well (FitzGerald et al. 1996; Tonin
et al. 1996; Abeliovich et al. 1997), and 45 such cases
is quite a compelling number to suggest the existence of
risk heterogeneity. Accordingly, the BCLC risk estimates
could actually prove correct for a proportion of the fam-
ilies identified through population-based studies,
whereas risks are much lower in others. Unless we learn
more about the nature of the other factors that code-
termine disease outcome in carriers, this poses a serious
barrier to individual risk assessment.
The BCLC also analyzed the proportions of families
with breast or ovarian cancer that could be attributed
to either BRCA1 or BRCA2, depending on the observed
phenotypes as defined by the number of breast cancer
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Table 2
Prevalence of BRCA2 Among Breast Cancer Patients in Founder Populations
Population and Geographic Origin Selection Criteria
Number
Tested
Number Positive
(%) Reference
Icelandic:
Population-based None 459 39 (8.5)a Johannesdottir et al. (1996)
Population-based None 632 49 (7.7)a Thorlacius et al. (1997)
Ashkenazim:
New York (Memorial Sloan-Kettering) Age !42 years 80 6 (7.5)b Neuhausen et al. (1996)
Boston metropolitan area Age !33 years 39 1 (2.6)b Krainer et al. (1997)
Israel (Jerusalem) None 178 8 (4.5)b Abeliovich et al. (1997)
New York metropolitan area None 268 8 (3.0)b Fodor et al. (1998)
Washington, DC, area None 288 11 (3.8)b Hartge et al. (1999)
a 999del5.
b 6174delT.
cases diagnosed before the age of 60 years, and the num-
ber of ovarian cancer cases (Ford et al. 1998). This anal-
ysis showed that, for example, in 69% of all families
with one case of ovarian cancer, the cases are due to
BRCA1. Such figures can be used to estimate the prior
probability that a woman is a BRCA1/BRCA2 carrier
on the basis of her family history of breast and/or ovar-
ian cancer. However, many BRCA1 and BRCA2 mu-
tation-screening studies of breast cancer and/or breast-
ovarian cancer families have consistently produced fewer
families with mutations than expected on the basis of
the BCLC estimates (reviewed at the Breast Cancer In-
formation Core website). This is explained partly by the
inability of any mutation-screening technique to pick up
all DNA changes in a gene. The most widely used screen-
ing modality (SSCP) still reaches a sensitivity of only
70%–80%, and even complete sequencing of all coding
regions could miss substantial proportions of carriers,
because it is PCR-based and would therefore miss large
genomic rearrangements. But more importantly, the fam-
ilies analyzed by the BCLC certainly do not represent a
typical cross-section of what is seen in cancer family
clinics. Many studies have analyzed a set of clinic-based
breast cancer families, often collected under much less
stringent criteria than those used by the BCLC. Such a
set more likely contains significant proportions of fam-
ilies either with a coincidental clustering of nongenetic
(or “sporadic”) breast cancer or with defects in genes
other than BRCA1 or BRCA2.
On the basis of observed population frequencies of
specific mutations in BRCA1 and BRCA2, one would
have predicted these disturbing factors to be less signif-
icant in the Jewish population. Logistic regression mod-
els based on data from families ascertained through can-
cer genetic screening clinics predicted, for example, that
∼40% of all probands with a family history of breast
cancer only, and an average age at diagnosis of !40
years, are carrying one of the three founder mutations
(Couch et al. 1997). Yet again, however, Hartge et al.
(1999) find only 26% in this category, and an even more
striking difference was observed when they compared
their data with predictions derived from another study
(Shattuck-Eidens et al. 1997).
Hartge et al. (1999) highlight several weaknesses in
their study, which may help explain these differences.
The survey did not constitute a random sample of the
entire Jewish community; genetic testing was confined
to the three known founder mutations, possibly neglect-
ing others; and family history data were restricted to
first-degree relationships, possibly missing a family his-
tory on the paternal side of the family. Yet these issues,
important as they are and worthy of further research,
do not interfere with the conclusion that the rationale
for genetic testing among Ashkenazi Jews has become
less apparent. Moreover, the issue of broad community
testing is not only driven by the cost effectiveness of the
test. As set forth above, important questions regarding
individual risk assessment in the carriers still remain
largely unanswered. Screening out those 9% carriers
among all Jewish breast cancer patients will leave 91%
testing negative, including quite a few with a significant
family history of breast cancer. What are the psycho-
logical side effects of leaving them in uncertainty about
their genetic risk? Or do we restrict screening to those
diagnosed before the age of 40 years and accept that we
will miss a number of carriers? This will need to be
weighed against the clinical benefits of determining car-
rier status. The efficacy of breast cancer screening in
premenopausal unaffected carriers is hedged with un-
certainty too, while chemoprevention is still in the re-
search phase. The acceptance of prophylactic mastec-
tomy, the only intervention that effectively reduces
breast cancer risks (Hartmann et al. 1999), may differ
considerably from woman to woman. The data of
Hartge et al. (1999) provide some useful estimates to
warrant careful policy making in these areas.
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